Preclinical Data Show Promise of Seribantumab in HER3-Positive Cell Lines

摘要

In this edition of Between the Lines, D. Ross Camidge, MD, PhD, and Alexander I. Spira, MD, PhD, examined preclinical data for seribantumab in patient-derived cell lines with NRG1 fusions.1